Ad-hoc Releases – Redcare

About us Newsroom

Careers Investor Relations

Loading...

Ad-hoc Releases

Redcare Pharmacy achieves 81% growth in Q3 Rx sales in Germany, 108% in September and decides to accelerate marketing in Q4 based on very convincing e-Rx metrics. Full-year guidance updated.

Redcare Pharmacy’s eHealth-CardLink solution approved by gematik today.

Redcare Pharmacy with internal succession plan due to the early departure of CCO Stephan Weber and CIO Marc Fischer at the Annual General Meeting on 17 April 2024.

Show More

Show Less

Redcare Pharmacy N.V. (formerly SHOP APOTHEKE EUROPE N.V.): Termination of voting pool agreement.

SHOP APOTHEKE EUROPE and GALENICA: Antitrust clearances for joint venture granted

SHOP APOTHEKE EUROPE N.V. and GALENICA AG enter into strategic partnership and establish a joint venture for the Swiss business; execution of capital increase.

SHOP APOTHEKE EUROPE N.V.: Olaf Heinrich shall become the new CEO

SHOP APOTHEKE EUROPE N.V.: No prolongation of his term as CEO by Stefan Feltens

Show More

Show Less

SHOP APOTHEKE EUROPE: ACQUISITION OF 'FIRST A', A PIONEERING QUICK-COMMERCE PLAYER IN THE GERMAN PHARMACY MARKET.

Show More

Show Less

SHOP APOTHEKE EUROPE: change of forecast for the 2021 financial year

SHOP APOTHEKE EUROPE: Pooling agreement of several shareholders with voting agreement for more than 26% of the voting rights.

SHOP APOTHEKE EUROPE N.V. increases size of the convertible bond offering due to high demand.

SHOP APOTHEKE EUROPE N.V. launches EUR 200 million convertible bonds.

SHOP APOTHEKE EUROPE Acquires Digital Health Provider SMARTPATIENT.

Show More

Show Less

SHOP APOTHEKE EUROPE N.V. ANNOUNCES REDEMPTION OF ITS EUR 135 MILLION 4.5% CONVERTIBLE BONDS DUE 2023.

SHOP APOTHEKE EUROPE N.V. ENDS DISCUSSIONS AND ANNOUNCES CLEAN-UP OF ITS EUR 135 MILLION 4.5% CONVERTIBLE BONDS DUE 2023.

SHOP APOTHEKE EUROPE N.V.:

SHOP APOTHEKE EUROPE N.V. ANNOUNCES TO START DISCUSSIONS OF A POSSIBLE EARLIER CONVERSION OF ITS EUR 135 MILLION 4.5% CONVERTIBLE BONDS DUE 2023.

SHOP APOTHEKE EUROPE raises full year 2020 guidance.

SHOP APOTHEKE EUROPE N.V. successfully completes EUR 65 million capital increase by placing c. 1.12 million new bearer shares with institutional investors on the back of very strong demand.

SHOP APOTHEKE EUROPE N.V. launches an equity offering of new bearer shares by way of an accelerated bookbuild.

SHOP APOTHEKE EUROPE N.V. successfully completes c. EUR 50m capital increase by placing 1.39m new bearer shares and a EUR 60m concurrent tap of its existing convertible bonds due April 2023 with institutional investors.

SHOP APOTHEKE EUROPE N.V. launches an equity offering of new bearer shares by way of an accelerated bookbuild and a concurrent tap issuance of its existing convertible bonds due April 2023.

SHOP APOTHEKE EUROPE: Revised forecast for financial year 2018

SHOP APOTHEKE EUROPE N.V.: Stefan Feltens to strengthen management team with immediate effect; will succeed Michael Köhler, who will resign as chair of the managing board for personal reasons as of 31 December 2018.

SHOP APOTHEKE EUROPE N.V. takes over specialist for functional nutrition products nu3 GmbH, Berlin

SHOP APOTHEKE EUROPE N.V. launches EUR 75 million convertible bonds offering with up to EUR 25 million increase option

SHOP APOTHEKE EUROPE to strengthen European market leadership through the acquisition of mail-order pharmacy Europa Apotheek.

SHOP APOTHEKE EUROPE N.V.: Comment on market rumors regarding a possible takeover by Amazon

SHOP APOTHEKE EUROPE sets IPO price at EUR 28.00 per share

Show More

Show Less